BioSpace News Archive

Kiora is advancing a pipeline of therapeutics for rare and underserved ophthalmic diseases -

Innovent Biologics, Inc. (Innovent) (HKEX: 01801) today announced that the first participant has been successfully dosed in a multicenter, randomized, double-blind, placebo-controlled phase 3 clinical trial (DREAMS-1) of mazdutide (Innovent R&D Code: IBI362), a glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, in Chinese patients with type 2 diabetes.

Minerva Biotechnologies, a private company developing 1st-in-human therapies for the treatment of solid tumor cancers, announced today that the FDA has approved their IND (Investigational New Drug) application to conduct clinical trials with huMNC2-CAR22, aka MUC1*-CAR-1XX, for the treatment of metastatic breast cancers.

Gensaic, a company that seeks to reimagine gene therapy, announced that it has received an investment from the CF Foundation to develop a gene therapy for Cystic Fibrosis.

Synchron, an implantable brain-computer interface (BCI) company, today announced the medical journal JAMA Neurology has published peer-reviewed, long-term safety results from a clinical study in four patients with severe paralysis implanted with Synchron’s first-generation Stentrode™, a neuroprosthesis device.

Novotech announced the acquisition of EastHORN, a European CRO with clinical, medical and regulatory expertise in multiple strategically important locations across the continent.

Novotech, the leading Asia Pacific centered biotech CRO today announced the acquisition of CBR International, a global product development, clinical oversight and strategic regulatory operations group.

Sanguine Biosciences announced a new investment from BroadOak Capital Partners, LLC, a leading direct investment and advisory firm focused on life science research tools, pharmaceutical services and diagnostics.

Sengenics Corporation LLC, driving the discovery of next-gen biomarkers through its immuno-proteomic platform, KREX®, and Summa Equity announce that Yvonne Linney PhD. has been appointed to the company’s Board of Directors, effective immediately.

Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts to attend its real-time, interactive presentation at the Emerging Growth Conference.